Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN) HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies BASEL, Switzerland and SYDNEY, Jan. 28, 2022 /PRNewswire/ HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel.
Allarity Therapeutics A/S: Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Lonza Group AG: Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complex
The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules
The investment is supported by a long-term collaboration and capital contribution with a major biopharmaceutical partner
The new manufacturing complex is designed to accommodate future small molecule expansions
Quote from Maurits Janssen, Strategic Business Development Small Molecules, Lonza: Supply is critical for our global partner in the oncology field. With this investment, we are enabling the treatment of many cancer patients. Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates. In addition, small molecule oncology therapies require specific technologies. These challenges were specifically taken i